The Research Prize Award was held during the second edition of the “Sanofi Diabetes Award” in partnership with STEDIAM –
Sanofi, a world leader in life sciences and a major stakeholder in diabetes, organized the 2nd edition of the “Sanofi Diabetes Award” in partnership with the Tunisian Society of Endocrinology Diabetes and Metabolic Diseases (STEDIAM).
This scientific event concerns the health professionals active in the development and the deployment of research projects related to the care of diabetic patients in Tunisia.
“Diabetes is a public health problem, especially in Tunisia. This is largely due to sedentary lifestyles and an unbalanced diet. Encouraging research to fight diabetes contributes to the fight against this disease, “said Dr. Chokri Jeribi, Country Chair of Sanofi Tunisia.
This second edition of the “Sanofi Diabetes Award” took place last Saturday, November 19th in Tunis with attendance of health professionals and other actors in charge of the diabetic disease in Tunisia.
5 research papers were presented to the Jury for this 2nd edition of the Sanofi Diabetes Award.
Dr. Ines Kammoun (Department of Endocrinology, INN, Tunis) and Dr. Asma Ben Abdelkrim (Department of Endocrinology, Farhat Hached, Sousse) were awarded first prize in ex quo.
“In addition to the recipients, all these works will be published in national and international scientific journals,” added Dr. Chokri Jeribi, Country Chair of Sanofi Tunisia.
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
MNHN (Entreprises Magazine)
Comments are closed.